Knowledge Library

WuXi AppTec in vitro Neuroscience Services

Neurological disorders, such as neurodegenerative diseases, epilepsy, chronic pain, psychiatric disorders, are one of today’s largest unmet medical needs. However, due to poor disease and target understanding, Neuroscience drug discovery can be very challenging. An open access research platform with dedicated neuroscience specialists and integrated services will be an ideal partner throughout your drug discovery …Read More >

Resource Type: Brochure
Resource Topic: Antibodies Biochemical Assays Biomarkers Cell-based Assays Cells and Protein Science Central Nervous System & Pain Hit Finding Hit-to-Lead in vitro biology Lead Optimization Phenotypic Assays Rare Diseases Safety and Early Toxicity Small Molecules Target Identification and Validation

VIEW

How Does It Work? | Peptibodies

#Research has explored the ways to extend the half-life of peptide drugs. One innovative way to achieve this is by fusing #therapeutic peptides to the Fc region of an antibody to create what is known as a peptibody. When the peptibody is naturally taken up by cells it binds to an Fc (antibody) receptor within …Read More >

Resource Type: Video
Resource Topic: Antibodies Cells and Protein Science Oncology Target-Specific Assays

VIEW

PD-1 Blockade Protein in 4th Generation Armored CAR-T Cells Enhances Cytotoxicity Effect with in vitro Re-challenge System

Chimeric antigen receptor (CAR)-T cells are genetically engineered T cells that express a surface receptor to recognize tumor-associated antigens (TAA). CAR-T cell therapy have demonstrated remarkable success with hematological malignancies. However, limited headway has been made towards solid tumor, due to various challenges, including recognition of tumor-specific antigen trafficking and penetration, localization and survival within …Read More >

Resource Type: Latest Science Poster
Resource Topic: Antibodies Biomarkers CAR-T Cell Cell Therapies Cell-based Assays Cells and Protein Science Oncology Target Identification and Validation

VIEW

OncoWuXi Newsletter: June 2022

WuXi AppTec xenograft and syngeneic tumor models in rats and CD47-related in vitro assay platform

Resource Type: Newsletter
Resource Topic: Antibodies Cell-based Assays Hit-to-Lead in vivo Pharmacology Lead Optimization Oncology Target-Specific Assays Tumor Models

VIEW

WuXi AppTec Discovery Services

Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platform. Integrated Chemistry and Biology Research Platform | From Discovery to Candidate Selection and Beyond

Resource Type: Brochure
Resource Topic: Antibodies Antibody Drug Conjugate Autoimmune and Inflammatory Diseases Biochemical Assays Biomarkers Biophysical Assays Candidate Selection CAR-T Cell Cardiovascular & Metabolic Diseases Cell Therapies Cell-based Assays Cells and Protein Science Central Nervous System & Pain Chemical Biology and Proteomics CRISPR/Cas9 Dermatology Discovery Chemistry DNA-Encoded Library (DEL) DRUG DISCOVERY AND INNOVATION Fragment-Based Drug Discovery Gene Manipulation Gene Therapies High-throughput screening (HTS) Hit Finding Hit-to-Lead Immunology in silico services in vitro biology in vivo Pharmacology in vivo Toxicology Infectious Diseases Lead Optimization Liver Diseases Mass Spectrometry-based Assays Metabolic Diseases NASH Oligonucleotides Oncology Oncolytic Viruses Ophthalmology Phenotypic Assays Quantum Mechanics Rare Diseases Respiratory Diseases Safety and Early Toxicity Screening Libraries Screening Services Small Molecules Structural Biology Target Identification and Validation Target-Specific Assays Targeted Protein Degradation TECHNOLOGY PLATFORMS THERAPEUTIC AREAS THERAPEUTIC MODALITIES Tumor Models

VIEW

Developing a panel of orthotopic syngeneic tumor models for IO drug discovery

Resource Type: Poster
Resource Topic: Antibodies in vivo Pharmacology Lead Optimization Oncology Target Identification and Validation Tumor Models

VIEW

Tumor evolution selectively inactivates the core microRNA machinery for immune evasion

Resource Type: Publication
Resource Topic: Antibodies CRISPR/Cas9 Immunology Oncology Screening Libraries Target Identification and Validation Target-Specific Assays Tumor Models

VIEW

Tumor evolution selectively inactivates the core microRNA machinery for immune evasion

Resource Type: Publication
Resource Topic: Antibodies Biomarkers Cells and Protein Science CRISPR/Cas9 Immunology Oncology Screening Libraries Target Identification and Validation Target-Specific Assays Tumor Models

VIEW

Cancer Immunotherapy and the Application of In Vitro Immunoassays in Drug Development

Resource Type: Webinar
Resource Topic: Antibodies Autoimmune and Inflammatory Diseases Biochemical Assays Cell-based Assays Hit-to-Lead Immunology Lead Optimization Oncology Phenotypic Assays Small Molecules Target Identification and Validation Target-Specific Assays

VIEW


Resource Topics